TY  - JOUR
PY  - 2022//
TI  - US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior
JO  - Journal of comparative effectiveness research
A1  - Voelker, Jennifer
A1  - Sheehan, John J.
A1  - Le, Hoa H.
A1  - Toro-Diaz, Hector
A1  - Li, Shujun
A1  - Joshi, Kruti
SP  - 319
EP  - 328
VL  - 11
IS  - 5
N2  - BACKGROUND: Esketamine nasal spray plus an oral antidepressant is approved in adults with major depressive disorder with acute suicidal ideation or behavior (MDSI). <br><br>METHODS: A budget impact analysis from a US payer perspective was performed with a hypothetical 1-million-member plan, using pharmacy and medical costs associated with adding esketamine plus an oral antidepressant to usual care. <br><br>RESULTS: Estimated annual total healthcare costs of managing patients with MDSI increased from $32,988,247 without esketamine to $34,161,188 in Year 3 with esketamine (primarily due to medical costs). The per-member-per-month incremental costs were $0.02, $0.06 and $0.10 in Years 1, 2 and 3, respectively. <br><br>CONCLUSION: Incorporation of esketamine results in a modest estimated impact on the annual budget over a 3-year time horizon.<p /> <p>Language: en</p>
LA  - en
SN  - 2042-6305
UR  - http://dx.doi.org/10.2217/cer-2021-0226
ID  - ref1
ER  -